Nuvectis says China grants breakthrough therapy designation to NXP200 for BRAF V600-mutant high-grade glioma

NVCT•2026-09-24

China’s drug regulator granted Breakthrough Therapy Designation to NXP200 for BRAF V600-mutant recurrent or progressive high-grade glioma. Nuvectis targets a U.S. IND filing in Q4 2026.

1. China designation

China’s drug regulator granted Breakthrough Therapy Designation to NXP200, developed by Haisco, for BRAF V600-mutant recurrent or progressive high-grade glioma. Nuvectis holds exclusive worldwide rights outside Greater China under a June 2026 licensing deal and targets a U.S. IND filing for NXP200 in Q4 2026.

Nuvectis says China grants breakthrough therapy designation to NXP200 for BRAF V600-mutant high-grade glioma

1. China designation

Related News

Oil gains on little sign of progress in US-Iran talks

Annexon presents Phase 3 ARCHER II baseline data for vonaprument geographic atrophy trial at Retina Society meeting

GEN Restaurant Group expands distribution through UNFI deal with SoFi Stadium, Olé City Market

Canada July retail sales fall 0.7%; seen up 1.3% in August

Clarivate accepts $75 million of 3.875% senior secured notes due 2028 in cash tender offer